NL-OMON25401RecruitingNot Applicable
A phase II study of sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) non-small lung cancer (NSCLC) with a K-Ras mutation.
Vrije Universiteit Medisch centrumPostbus 70571007 MB AmsterdamNetherlands0 sites46 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 46
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. Histologically advanced NSCLC stage IIIB or IV harbouring a K-RAS mutation;
- •2. Disease progression after at least 1 prior chemotherapy regimen that should include a platinum doublet;
Exclusion Criteria
- •Excluded medical conditions:
- •1. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arythmias requiring anti-arythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension;
Investigators
Similar Trials
Completed
Phase 2
Phase II study of sorafenib in patients with advanced hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000002972Kyorin University Hospital80
Completed
Phase 2
A PHASE II STUDY OF SORAFENIB IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC (STAGE IIIB OR IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH A K-RAS MUTATIO10038666non-small cell lung cancerNL-OMON32472Vrije Universiteit Medisch Centrum48
Active, not recruiting
Phase 1
A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic CarcinomaEUCTR2008-000066-22-GBChristie Hospital NHS Foundation Trust
Recruiting
Phase 2
Phase II study of sorafenib-regorafneib sequential therapy for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190082Yamashita Tatsuya33
Completed
Phase 2
Phase II study of sorafenib with S-1 for advanced hepatocellular carcinoma.Hepatocellular carcinomaJPRN-UMIN000007199Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University25